Bod Lenses

# INVESTOR PRESENTATION

August 2026

One
life - see
it well.

Bod Lenses

# Table of Contents



One
life - see
it well.

Vilnius · August 2026

# Important notice

**This Investor Presentation (the "Presentation") is neither considered as a prospectus as defined in Regulation No. 2017/1129, nor information document as defined under the Law on Securities of the Republic of Lithuania. Moreover, this Presentation is not approved by any financial supervision authority of the Republic of Lithuania or any securities regulation authority of any other jurisdiction as such.**

By attending a meeting where this Presentation is presented, accessing, downloading, reading, or otherwise making available to yourself any content of the Presentation, in whole or in part, you hereby agree to be bound by the following limitations, notifications and accept the terms and conditions as set out below.

This Presentation is provided to you for information purposes only. You should not rely upon it or use it to form the definitive basis for any decision, contract, commitment or action whatsoever. BOD Lenses, UAB (the "**Company**") has taken all reasonable care to ensure that the information contained in this Presentation is reliable, but no guarantees, warranties or representations are made as to the accuracy or completeness of the information contained in this document. This Presentation shall not be deemed to be financial advice from the Company to any potential investor.

This Presentation includes description of the Company and its business. It is furnished to you solely for your information and you may not reproduce it (or any part of it) or redistribute it (or any part of it) to any other person or otherwise divulge, directly or indirectly, its contents to any person. This Presentation does not constitute or form part of, and should not be construed as, an offer, solicitation, financial promotion or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company.

This Presentation is intended for discussion purposes only and does not create any legally binding obligations on the part of the Company. This Presentation is not intended to form the basis of a decision to purchase securities or any other investment decision and does not constitute an offer, invitation or recommendation for the purchase of securities. This material is: (i) for your information, and we are not soliciting any action based upon it; (ii) not to be construed as an offer to sell or a solicitation of an offer to buy any security in any jurisdiction where such offer or solicitation would be illegal; and (iii) based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. When making an investment decision, you should rely solely on the Information Document and not the summary contained herein.

When reviewing the information, please note that past performance is no guide to or guarantee of future performance. You should be aware that ideas and potential opportunities discussed herein carry risk, that the value of described assets can vary over time, and that potential investors may not get back the full amount invested.

This Presentation includes forward-looking statements. These statements may be identified by such words as "aim", "target", "expect", and similar expressions, or by their context. These statements are made on the basis of current knowledge and assumptions and address matters that involve risks and uncertainties. Accordingly, no assurance is given that such forward-looking statements will prove to have been correct. You should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update or correct any inaccuracies which may become apparent after the date of this presentation.

The distribution of this Presentation may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein come should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

The transaction mentioned herein may not be appropriate for all individuals and/or investors and before entering into any transaction you should take steps to ensure that you fully understand such transaction and have made an independent assessment of the appropriateness of such transaction in the light of your own objectives and circumstances, including the possible risks and benefits of entering into such transaction.

The Company urges all persons considering investment opportunities to seek professional legal, regulatory, accounting, tax or other type of advice, as may be appropriate, on all relevant issues in considering investments in securities.

This Presentation is subject to Lithuanian law (disregarding any conflict-of-laws rules which might refer the dispute to the laws of another jurisdiction), and any dispute arising in respect of this Presentation is subject to the exclusive jurisdiction of Lithuanian courts.

# EXECUTIVE SUMMARY

**BOD Lenses is an independent B2B manufacturer of prescription (Rx) ophthalmic lenses based in Vilnius, Lithuania, and forms part of BOD GROUP. The BOD GROUP's engineering and high-technology manufacturing experience dates back to 1998, while the ophthalmic lens business was established in 2014 as a new strategic business area of BOD GROUP. BOD Lenses specialises in digitally manufactured, individually customised Free-Form prescription (Rx) lenses and operates one of the most modern independent ophthalmic lens laboratories in Northern Europe.**

**The business has subsequently developed into the largest Rx ophthalmic lens laboratory in the Baltics, with current production capacity of up to approximately 4,000 prescription lenses per day. Production is operated on a 24/7 basis, while over 80% of output is exported to 31 countries.**


## Summary of the key Terms of the Bonds

| | |
|---|---|
| **Issue size** | Up to EUR 4 000 000 |
| **Nominal value** | EUR 1 000 |
| **Interest rate** | Set by auction as 9%, 9.5% or 10% |
| **Interest payment frequency** | Monthly |
| **Issue date** | 2026.09.02 |
| **Maturity date** | 2028.10.02 |
| **Primary distribution** | Public offering in Lithuania, Latvia and Estonia |
| **Use of proceeds** | Proceeds from the issuance will be used to refinance maturing bonds under LT0000409575 issued by the Global BOD Group SIA. |
| **Financial covenants** | Adjusted equity ratio >=20%<br>Debt/EBITDA (including guaranties) <=5<br>ICR > 2.00 |
| **Lead Manager** | AB Artea Bankas |
| **Legal Advisor** | TEGOS |
| **Trustee** | UAB Audifina |
| **Subscription period of the first tranche** | 24 August 2026 – 31 August 2026 at 15:00 (Vilnius time) |
| **Listing** | Application will be made for Bonds to be admitted on the Issue date for listing and trading on the Nasdaq First North |

One life - see it well.

Bod Lenses

# COMPANY OVERVIEW

One
life - see
it well.

# COMPANY AT A GLANCE

- B2B manufacturer of prescription (Rx) ophthalmic lenses — part of Global BOD Group, based in Vilnius, with 20+ years of industry experience.
- Lens business launched in 2014 on the group's thin-film coating heritage; fully automated digital production.
- FY2025 revenue €13.21M (+0.2% YoY) with a net profit of €0.38M.
- Exports ~80% of output to 31 countries; ~115 employees.
- Capacity up to 4,000 Rx lenses/day, running 24/7 — one of the largest labs in the Baltics. 100% Green energy usage.
- Lenses produced with green energy from the group's own SoliTek solar plants.
- ISO, FDA certified laboratory.

# COMPANY VISION

**By 2029, BOD Lenses is a manufacturer of individualized RX lenses and a leader in implementing innovations, providing optical businesses worldwide with top-quality products and vision solutions.**

One
life - see
it well.

# PRODUCTS AND TECHNOLOGIES

## LENS TYPES

- SINGLE VISION LENSES
- PROGRESSIVE LENSES
- BIFOCAL LENSES
- INDOOR LENSES
- LENSES FOR CHILDREN

## MATERIALS

- TRANSITIONS
- NEOCHROMES
- SOLIS II
- POLARO
- NUPOLAR
- ASPHERIC
- BLUE 420
- TRILOGY

## COATINGS

- ULTRASLIK
- SERICUM UV
- CLARUS II
- ACHROMATIC
- BLUE PRO
- MIRROR
- FLASH TO MIRROR

## TECHNOLOGIES

- COLOR SIGHT
- DIGITAL RAY-PATH 2
- CAMBER
- STEADY PLUS
- STEADY

## TINTING

- NUPOLAR
- TINTED UNIVERSE
- TINTING
- NANO TINTING

One
life - see
it well.

# GROUP HISTORY

| Year | Milestone |
|---|---|
| **1998** | Founded as Baltic Optical Disc — the first industrial CD plant in Eastern Europe (Vilnius, later Tallinn); core competence in ultra-thin coatings. |
| **2009** | SoliTek founded (solar cells & modules), built on the same coating-technology base. |
| **2014** | BOD Lenses business and factory launched; Schneider GmbH Modulo line installed within 9 months; Global BOD Group holding formed. |
| **2020** | All production moved to the group’s technology centre (LIGHT WING building, Mokslininkų g. 6A, Vilnius). |
| **2021** | CD business sold; the group focuses on two pillars — solar (SoliTek) and lenses. |
| **2023–24** | Bond issuance; export map grows to 31 countries. |

# BOD LENSES HISTORY

- **1998** — CD/DVD business is born
- **2009** — Solar energy business is born
- **2013** — L.I.G.H.T. WING The greenest industrial building in Europe
- **2015** — Optical lenses business is born
- **2021** — Full lab automation and robotization
- **2021** — Industry 4.0 digital advancement and transformation award
- **2022** — In-house lens quality testing lab
- **2023** — Bod Frames business
- **2023** — 1st Sustainability Report
- **2024** — Tinting department expanded

One life - see it well.

# INVESTMENT HIGHLIGHTS


- ✓ FY2025 revenue €13.21M (+0.2%); Net profit (~€0.38M)
- ✓ 2026 Jan–Jun revenue €7.74M (+9%), 37% gross margin, ~€0.9M EBITDA
- ✓ ~80% exported to 31 countries; 2–3 new markets per year
- ✓ Defensive ~€4.7bn European lens market growing ~4.6% a year
- ✓ Independent B2B model + German technology + Baltic cost base

# BUSINESS & OPERATIONS

- B2B only — sells to independent optical stores and national distributors, with no retail arm, so it never competes with its own customers.
- White-label enablement: branded packaging, lens passport cards, localized catalogues, IT integration and the opticalo.eu online ordering platform.
- Fully automated Schneider Modulo line; capacity up to 4,000 Rx lenses/day; 48-hour order-to-delivery.
- Lead time cut 48%; moved from 24/5 to 24/7 and 3→4 shifts at the same cost and headcount.
- Manufactured with green energy from the group's own SoliTek solar facilities; premium coatings carry a 36-month warranty.

# PRODUCTS/MARKETS AND GROWTH STRATEGY

- **Broad Rx portfolio** — single vision, bifocal, digital / anti-fatigue and free-form progressive lenses, covering both everyday and premium vision needs, stock offer.
- **Core product families** — Mono, Okos+, Effecto+, Velveto+, Compass Lens and Multifit.
- **Premium offering** — licensed brands (**Transitions**, **NuPolar, Enchroma, Neurolens, Neochromes**),materials and a coatings ladder up to **Clarus Sericum UV, Achromatic, UltraSlik**.
- **Premium mix strengthening** — premium products represented **78.3% of sales volume** in **Jan–Jun 2026**, up from **66.9%**a year earlier.
- **International footprint** — shipping to **31 countries**, with approximately **84% of output exported**.
- **Customer base expansion** — active customers increased from **365 to 418** in **Jan–Jun 2026** (**+14.5%**).
- **Top 2026 markets** *(Jan–Jun)* — **Lithuania 16.1%**, **UK 12.2%**, **Spain 11.6%**.

- BOD Lenses' expansion strategy focuses on **geographic diversification and export growth**, strengthening its position in existing markets and strategically targeting countries with the greatest potential. Priority expansion markets include **Germany, the Netherlands, Switzerland, the United Kingdom, Poland, and North America**, while maintaining strong positions in the Baltic and Southern European markets.
- Commercial growth will be based not only on increasing the **number of customers** but also on generating **greater value per customer**. The focus is on premium product penetration, long-term B2B and white-label partnership models, and the development of new product categories. Priority is given to projects capable of generating recurring and profitable revenue.
- **Operational efficiency** is one of the key drivers of our growth. We will continue to automate production, warehousing, order processing, logistics, and reporting processes to increase capacity without a proportional increase in staff or costs. The main goal is to improve productivity, order fulfilment speed, quality, and EBITDA per employee.
- Strategic Goal – to achieve an annual revenue of €30 million by 2030 through profitable and stable growth: by expanding into new markets, deriving greater value from existing customers, offering premium products, and operating more efficiently.

# PLANNED INVESTMENTS AND EXPANSION PLANS

The planned investments of 1.9 M Eur are primarily aimed at eliminating the current production bottleneck in the lens generating department and **increasing its capacity from approximately 4,000 to 5,500 lenses per day**.
In parallel, BOD Lenses plans to further increase the level of production automation by integrating additional robotic solutions and new conveyor systems into the existing production line. This will improve production efficiency, reduce manual handling and support higher production volumes. The investment in new anti-reflective coating equipment is also intended to ensure production continuity and operational reliability, as the existing equipment is ageing and experiencing an increasing frequency of technical failures.

BOD Lenses intends to continue expanding and modernising its manufacturing capabilities over the coming years. The Company's **strategic objective** is to increase its total production capacity to approximately **8,000 lenses per day by 2030**.

This growth will be supported by continued **investments in**:
- manufacturing efficiency and capacity expansion;
- automation and robotisation of production processes;
- increased employee productivity and process optimisation; and
- implementation of new technologies and innovations in response to evolving market requirements.

These investments will enable BOD Lenses to support further business growth, improve production efficiency and scalability, and strengthen its ability to serve increasing demand across its international markets.

# SUSTAINABILITY AT THE CORE

**Bod Lenses ESG goals are aligned with the United Nations Sustainable Development Goals (SDGs), focusing on the priority sustainability areas below.**

## ENVIRONMENTAL




## SOCIAL




## GOVERNANCE


One life - see it well.

## Green Products Made With Green Energy Only

- Solar panels manufactured using 100 % green power
- 250 kW solar power plant on the roof
- 105 geothermal boreholes (10.4 km of geothermal energy)

## Fully Energy-Autonomous Building

- 850 kW solar power plant: on roof & façade
- 80 geothermal boreholes (15,75 km of geothermal energy)
- Not connected to the city heating system
- A++ energy class

# TECHNOLOGY DEVELOPMENT PARTNERS

SCHNEIDER

IOT

LensWare

satisloh

MEI

AR Automation & Robotics

enchroma

neurolens® Relief is in Sight

HORIZON™ EYE CARE

One
life - see
it well.

# BOD LENSES STRUCTURE

**SHAREHOLDERS**

- **Vytautas Tuminas 15%**
- **BOD Lenses AS 16.25%**
- **Global BOD Group SIA 68.75%**

**UBO**
**Vidmantas Janulevičius 80.67%**
**Vladas Sakalauskas 19.33%**

---

**Vytautas Tuminas, CEO of BOD Lenses**

**Production Manager**
**Evaldas Pažemeckas**

1. Managing and ensuring the production process;
2. Improving production efficiency and quality;
3. Managing the production team and resources.

**Head of Technology and Quality**
**Lukas Jočionis**

1. Management and improvement of technological processes;
2. Quality assurance and control;
3. Team and quality system development;
4. Planning and implementation of growth strategies.

**Commercial Manager**
**Povilas Steponavičius**

1. Sales strategy and management;
2. Management of commercial operations and teams;
3. Market and customer development.

# THE TEAM

**Vytautas Tuminas**
**CEO**

Vytautas leads BOD lenses for more than 11 years, with 13 years of management experience in manufacturing companies and another 11 years in public sector roles

He holds MBA degree from BMI Institute and Masters degree in Banking and Finance from Vilnius University

**Evaldas Pažemeckas**
**Production Manager**

Evaldas has acted as a production manager for more than 7 years in BOD Lenses

He holds Masters degree in Biomechanic Engineering from Vilnius Gediminas technical university

**Lukas Jočionis**
**Head of Technology and Quality**

Lukas has been with BOD lenses for more than 6 years in quality and technology roles

He holds degree in Physics from Vilnius University

**Povilas Steponavičius**
**Chief Commercial Officer**

Povilas has been in this role with BOD Lenses for more than 5 years, with 20 years of sales experience in various companies

Povilas studied Business management & administration at Vilnius University

Bod Lenses

# FINANCIAL OVERVIEW

One
life - see
it well.

# FINANCIAL HIGHLIGHTS

| €m | 2024 | 2025 | 2026 H1 (Unaudited) |
|---|---|---|---|
| **Revenue** | 13.2 | 13.2 | 7.7 |
| **Revenue growth** | — | +0.2% | +9% |
| **Gross profit** | 5.1 | 4.9 | 2.8 |
| **Gross margin** | 38.5% | 37.2% | 36.4% |
| **EBITDA** | 1.7 | 1.4 | 0.9 |
| **EBITDA margin** | 12.7% | 10.7% | 11.7% |
| **Net profit** | 0.5 | 0.4 | 0.5 |
| **Net margin** | 4.0% | 3.7% | 6.5% |
| **Total Assets** | 7.4 | 10.9 | 8.5 |
| **Total Liabilities** | 4.9 | 7.8 | 4.9 |
| **Total Equity** | 2.4 | 2.8 | 3.5 |

## Key takeaways

- Revenue momentum improved: 2025 revenue remained stable at €13.2m, while 2026 H1 revenue reached €7.7m, +9% YoY.
- Profitability improved: EBITDA margin improved to 11.7% in H1 2026 vs. 10.7% in 2025, although still below 2024 levels.
- Strong bottom-line performance: H1 2026 net profit of €0.5m already exceeds FY2025 (€0.4m), with net margin rising to 6.5%.

Bod Lenses

# BOND OFFERING

One
life - see
it well.

# BOND TERMS & STRUCTURE

| | |
|---|---|
| **Issuer:** | **UAB BOD Lenses** |
| **ISIN:** | LT0000138653 |
| **Status of the Bonds:** | Secured by Surety |
| **Specified Currency:** | Euro (EUR) |
| **Aggregate Nominal Amount:** | EUR 4,000,000 |
| **Issue Price:** | EUR 1,000 |
| **Specified Denominations:** | EUR 1,000 |
| **Issue Date:** | 2 September 2026 |
| **Maturity Date:** | 2 October 2028 |
| **Subscription period:** | 24 - 31 3PM August 2026 |
| **Use of proceeds:** | The proceeds of the issue of Bonds will be used to refinance maturing bonds under ISIN LT0000409575. |
| **Financial covenants:** | Adjusted equity ratio >=20%, Debt/EBITDA (including guaranties) <=5, ICR > 2.00 – tested semi-annualy |
| **Special underatkings** | Global BOD Group loan subordination, limits on dividends, restriction on disposal of assets and de-mergers if it has material adverse change, financial reporting, restriction on lending except for Global BOD Group for the purpose of redeeming its bonds under ISIN LT0000409575. |
| **Surety provider:** | UAB „Soli Tek Cells“ |
| **Trustee:** | UAB “Audifina” |
| **Lead Manager** | AB Artea bankas |
| **Legal advisor:** | TEGOS |
| **Fixed Rate Bond Provisions** | |
| (i) Interest Rate: | The annual interest rate will be set by auction as 9%, 9.5% or 10%.The final annual interest rate will be determined in accordance with the Section V “Subscription and Sale of the Bonds” of the Information Document. |
| (ii) Interest Payment Date(s) and (iii) Day Count Fraction: | Monthly, 30E/360 |
| **Call Option** | Bonds may be in whole or partially redeemable at the option of the Issuer prior to their Maturity Date in accordance with the following conditions:<br>• early redemption may occur at the discretion of the Issuer on or after the date falling 6 (six) months after the Issue Date;<br>• if early redemption date occurs on or after the date falling 6 (six) months after the Issue Date but earlier than the date falling 12 (twelve) months after the Issue Date, the respective Early Optional Redemption Amount will be equal to 101.00% of Nominal Amount plus accrued Interest from the last Interest payment date;<br>• if early redemption date occurs on or after the date falling 12 (twelve) months after the Issue Date but earlier than the date falling 18 (eighteen) months after the Issue Date, the respective Early Optional Redemption Amount will be equal to 100.50% of Nominal Amount plus accrued Interest from the last Interest payment date;<br>• if early redemption date occurs on or after the date falling 18 (eighteen) months after the Issue Date, the respective Early Optional Redemption Amount will be equal to 100.00% of Nominal Amount plus accrued Interest from the last Interest payment date. |
| **Put Option** | Change of Control, De-listing Event or Listing Failure |
| **Form of Bonds**: | The Bonds shall be issued in non-material registered form. The book-entry and accounting of the dematerialized securities in the Republic of Lithuania shall be made by Nasdaq CSD. Entity to be in charge of keeping the records will be the Issuer. The Bonds shall be valid from the date of their registration until the date of their redemption. No physical certificates will be issued to the Investors. Principal and interest accrued will be credited to the Bondholders’ accounts through Nasdaq CSD. |
| **Governing Law:** | The Bonds, and any non-contractual obligations arising out of or in connection therewith, shall be governed by and construed in accordance with the laws of the Republic of Lithuania. |
| **Jurisdiction:** | Any dispute or claim arising out of or in relation to the Bonds, including any non-contractual obligation arising out of or in connection with the Bonds, shall be finally settled by the courts of the Republic of Lithuania. |

# SUBSCRIPTION/ PAYMENT /ALLOCATION/SETTLEMENT (1/3)

**Subscription Procedure for Existing Boldholders**
By filing a respective corporate event notification to the Nasdaq CSD, the Issuer will offer to all Existing Bondholders to exchange the Existing Bonds for new Bonds to be issued under this Information Document. The Existing Bondholders during the Subscription Period may exchange their Existing Bonds for the Bonds by submitting an order for exchange (the “Exchange Order”) to their Custodian using the offer form provided by the Custodian. Where “Custodian” means a Nasdaq CSD participant directly, or licensed credit institution or investment brokerage company that has a financial securities’ custody account with Nasdaq CSD participant.

An Existing Bondholders may submit an Exchange Order only when there is a sufficient number of the Existing Bonds on their securities account. The exchange ratio is 1-to-1 and any number. If the number of the Existing Bonds which are blocked is insufficient, the exchanged order shall be deemed valid only in respect to the number of the Existing Bonds that are on the Existing Bondholder’s securities account.

Each Existing Bondholder by submitting an Exchange Order authorises and instructs the Custodian to immediately block the total number of the Existing Bonds to be exchanged with the Bonds on the Existing Bondholder’s securities account until the settlement of Bonds is completed. The number of the Existing Bonds on the Existing Bondholder’s securities account to be blocked shall be equal to the total number of the Existing Bonds to be exchanged with the Bonds.

Custodian charges or any other charges, including any applicable commissions of the relevant Custodian, relating to the execution of the Exchange Order shall be borne separately by the Existing Bondholders. Such charges cannot be quantified by the Company.

**General Subscription procedure for all other Investors**
In order to subscribe for the Bonds, the Investor must have a securities account with the Exchange Member and fill in a subscription order (the "Subscription Order") form provided by the Exchange Member during the Subscription Period only in order for the Exchange Member to enter a buy order in Nasdaq’s trading system. The Subscription Orders shall be submitted by means accepted and used by the Exchange Members (e.g., physically, via the internet banking system and/or by any other available means). Bank charges or any other charges, including any applicable commissions of the relevant market institutions, relating to the payment of the subscription price shall be borne separately by the Investors. Such charges cannot be quantified by the Company or the Dealer.

**Preferred Interest Rate (coupon)**
The Issuer may offer the Bonds for a fixed annual interest rate as already specified in the Final Terms or within a range as specified in the Final Terms. In case the Issuer offers the Bonds for a fixed annual interest rate within a range as specified in the Final Terms, each Investor undertakes to specify the investment amount(s) the Investor is willing to invest at one or more annual interest rate (coupon) levels within the available annual interest rate (coupon) range as indicated by the Issuer. For the avoidance of doubt, the Investor may subscribe the Bonds on different preferred annual interest rate (coupon) levels. By submitting the Subscription Order, the Investor acknowledges that, in case the Issuer offers the Bonds for a fixed annual interest rate within a range as specified in the Final Terms, each investment amount to be invested per each offered preferred annual interest rate has to be not less than the Minimum Investment Amount as specified in the Final Terms. Otherwise, the Subscription Order for subscribing to the Bonds with the less than Minimum Investment Amount shall not be considered valid and shall not be processed.

# SUBSCRIPTION/ PAYMENT /ALLOCATION/SETTLEMENT (2/3)

**Setting Interest Rate (Coupon)**
The Investors acknowledge that the Interest Rate (coupon) of the Bonds shall be determined upon the discretion of the Issuer within the range indicated in the Final Terms, taking into consideration, among other factors, the volume and price level of Subscription Orders received from the Investors. All Investors who have been allocated the Bonds of the relevant Tranche shall pay the same price and receive the same fixed annual interest rate for the Bonds. The Investors will be informed about the final annual Interest Rate (coupon) upon allocation.

**Payment for the Bonds**
By submitting a Subscription Order each Investor authorises and instructs the Exchange Member through which the Subscription Order is submitted to immediately block the whole subscription amount on the Investor’s cash account connected to its/his/her securities account until the settlement is completed or funds are released in accordance with these terms and conditions. In case the Issuer offers the Bonds for a fixed annual interest rate within a range as specified in the Final Terms and the Investor has placed Subscription Orders at different preferred annual interest rates, the total transaction amount to be blocked will correspond to the sum of investment amounts (in EUR) payable per each Investor’s offered preferred annual interest rate level. For illustrative purposes only, assuming the Investor has placed the following Subscription Orders:

| Preferred annual interest rate (%) of the Bonds in a range of x% - z% | Investment amount (EUR) (per each offered interest rate) |
|---|---|
| x% | EUR 20,000 |
| y% | EUR 40,000 |
| z% | EUR 60,000 |

The amount of EUR 120,000 shall be the transaction amount and it will be blocked on the Investor's cash account until the settlement is completed or funds are released.
Transaction related charges of the financial institution operating the Investor's securities account may also be blocked on the cash account as agreed between the Investor and the financial institution operating the Investor's securities account. Examples for illustrative purposes only are provided in paragraph „Allotment of the Bonds to the Investors“ of Section V “Subscription and Sale of the Bonds” of the Information Document.

**Allotment of the Bonds to the Investors**
After expiry of the relevant Subscription Period, the Issuer on its sole discretion together with the Lead Manager shall decide which Investors shall be allotted with the Bonds and to what amount, and which Investors shall not be allotted with the Bonds.
The Bonds will be allocated to Investors by the Issuer on the Allocation Date indicated in the Final Terms. In case the Issuer offers the Bonds for a fixed annual interest rate within a range as specified in the Final Terms, only Subscription Orders which are at or below the set final Interest Rate (coupon) will be subject to allocation.

# SUBSCRIPTION/ PAYMENT /ALLOCATION/SETTLEMENT (3/3)

**Payment for the Bonds**
By submitting a Subscription Order each Investor authorises and instructs the Exchange Member through which the Subscription Order is submitted to immediately block the whole subscription amount on the Investor's cash account connected to its/his/her securities account until the settlement is completed or funds are released in accordance with these terms and conditions.
Existing Bondholders may pay for the subscribed Bonds with the redemption funds of the bonds (ISIN LT0000409575). In such case, the subscription price of the Bonds payable by the Existing Bondholders will be set off with the redemption proceeds of the bonds (ISIN LT0000409575) on the Settlement Date.

**Allotment of the Bonds to the Investors and Existing Bondholders**
Bonds will be allocated by giving priority to the Subscription Order of Existing Bondholders and the scope of the Subscription Orders satisfaction is not greater than the nominal value of the bonds (ISIN LT0000409575). After expiry of the relevant Subscription Period, the Issuer on its sole discretion together with the Lead Manager shall decide which Investors shall be allotted with the Bonds and to what amount, and which Investors shall not be allotted with the Bonds.
By placing a Subscription Order the Investors shall be considered as have consented to being allotted a lower number of Bonds than the number specified in such Investor's Subscription Order, or to not being allotted any Bonds at all, pursuant to this Information Document.

**Return of funds to Investors**
If the Offering or a part thereof is cancelled, or if the Investor has not been allotted any Bonds, or allotted a lower number of Bonds than the number specified in such Investor's Subscription Order / Exchange Order, or the Subscription Order / Exchange Order has been cancelled or rejected, the funds blocked on the Investor's cash account, or the excess part thereof (the amount in excess of payment for the allocated Bonds), will be released by the respective Exchange Member or the Leader Manager and pursuant to its agreement with the investor.
Regardless of the reason for which funds are released, neither the Issuer nor the Lead Manager shall be responsible for any relationships between the Investor and Exchange Member in connection with any operations happening on the cash account connected to the Investors' Securities Account.

**Settlement**
Settlement Date is indicated in the Final Terms.

For investors. Settlement of the Bonds will be executed through the Nasdaq CSD settlement system as DVP (Delivery versus payment) transactions according to the applicable Nasdaq CSD rules. The Bonds assigned to the Investor will be recorded in the Investor's securities account not later than within 3 (three) business days from the Settlement Date.

For Existing Bondholders. On the Settlement Date, the Nasdaq CSD will delete a number of the Existing Bonds that were exchanged for the Bonds from each of the financial institution account and transfer the Bonds to a relevant financial institution account, which in turn will transfer specific number of the Bonds to each of the Existing Bondholder.

# RISK FACTORS I

## Issuer specific risk factors

***Market and Customer Risk***

The majority of the Issuer's revenue is generated in export markets. Notwithstanding, that the Company is diversifying sales across different geographic markets, expanding operations in Germany, the Netherlands, Switzerland, the United Kingdom, Poland, and North America, and developing long-term B2B and white-label partnerships, the operating results may be affected by economic conditions in key European markets, changes in consumer behaviour, and intensifying competition. In addition, the demand for ophthalmic lenses correlates with economic activity, including growth in gross domestic product and retail trade, in the countries in which the Company operates. Although the ophthalmic industry is normally considered to be less sensitive to economic cycles than number of other industries, both weak and strong economic activity, presents a challenge for the Company. Thus, periods of recession may have an adverse impact on payment terms and on the demand for services. This may adversely affect the Company's financial performance and financial conditions.

***Supply chain and Counterparty risk***

Some of the key raw materials, stock lenses, and production materials are purchased from suppliers in China, India, the U.S., and other non-EU countries. Geopolitical changes, such as military conflicts, e.g., between Iran and Israel, transportation disruptions, and changes in customs or other trade restrictions may affect delivery times and cost of goods sold. Notwithstanding, that the Company is aiming to maintain alternative suppliers, monitor inventory levels of critical raw materials, and diversify supply sources, the supply chain and counterparty risk may result in financial losses, including, but not limited to, revenues not being received from customers, funds deposited at banks, partners in long term projects failing to perform their obligations etc. to the Issuer. Default of the Issuer's counterparty may affect the completion of the Issuer`s commenced investment projects, the quality of goods provided by the Issuer or harm the Issuer's reputation.

***Production and Business Continuity Risks***

The Issuer's operations depend on the uninterrupted operation of specialized production equipment, automated processes, and information systems. Major equipment failures or IT system disruptions could temporarily reduce production capacity and affect order fulfilment times. Accordingly, this risk is mitigated by integrating production algorithms (for the Issuer's product portfolio) across alternative Rx manufacturing facilities globally, as well as by performing preventive equipment maintenance, maintaining inventories of critical components and consumables, and continuing to automate and standardize operational processes. Nonetheless, a failure or interruption in the operation of these systems cannot be ruled out. Failures or interruptions in the operation of the equipment and/or IT systems used by the Issuer could result in loss of business and/or cause reputational damage to the Issuer. This could have a material adverse effect on the net assets, financial position and financial performance of the Issuer.

# RISK FACTORS II

***Risks Related to Growth and Investment Implementation***

The Issuer's strategy calls for significant geographic expansion, the development of new product categories, and improvements in manufacturing efficiency. Expansion projects may require additional investments and managerial resources, and their commercial results may be achieved later than planned. Therefore, investments and new market projects are implemented in phases, with priority given to initiatives that have clear potential for long-term, recurring, and profitable revenue. Nonetheless, the success of the new market projects cannot be guaranteed and are subject to variation due to numerous factors. The Company's financial results might not develop as projected because of a lower global demand, increased competition or the Company's inability to implement its business strategy. In addition, the management may fail to correctly anticipate future market trends and make worse than optimal decisions regarding future development of the Company.

***Company's liquidity and dependence on external financing***

In addition to other financial ratios, the Company calculates comparative values of the current ratio. Although the values of the current ratio of the Company (on consolidated basis) as of 30 June 2026 are larger than 1 (equal to 1.74), a theoretical risk remains that circumstances could appear in which the Company would fulfil its current obligations only partially. Accordingly, the decrease of Company's liquidity ratio can appear due to deterioration of amounts receivable or stock. In addition, as of 30 June 2026, the Issuer's consolidated borrowings and other financial debts constituted EUR 1,651,200 (or 19% of total Company's assets as of 30 June 2026).

In addition, the existing credit facilities of the Companies contain financial covenants (for example, restrictions on borrowing and dividends, etc.) and provide for certain other obligations and representations the violation of which may lead to an event of default and acceleration of the loans. Moreover, the Company's ability to comply with covenants and restrictions contained in the loan agreements may be affected by events beyond its control, including, without limitation, prevailing economic, financial, legal and industry conditions. In the event that these obligations were to be breached, the creditors would be able to declare an event of default pursuant to the relevant agreements and require repayment of the entire outstanding amounts. Thus, such events may cause interruptions in regular business activities, loss of collateral or, in extreme cases, a financial distress for the Issuer.

***Currency Risk***

The majority of the Issuer's sales and purchases are conducted in euros. Nonetheless, some purchases from China and sales in the U.S. are conducted in U.S. dollars. Consequently, changes in the EUR/USD exchange rate may affect the cost of acquiring raw materials and goods, as well as the Company's profitability. This risk is monitored by assessing the volume of currency-denominated liabilities and, when necessary, by applying pricing or other risk management measures. However, changes in foreign exchange rates (particularly fluctuations between EUR/USD) can affect the Issuer's competitiveness and cost structure. The Issuer's ability to renegotiate the currency-related cost increases with the suppliers may be limited by competitive dynamics or contractual terms. Thus, significant or sustained adverse movements in exchange rates could therefore have a material adverse effect on the Issuer's business and financial results, however, currently the trade levels in USD constitute less than 2% of company's revenue thus are deemed not material at this moment.

# RISK FACTORS III

***Operational and safety risks***

Issuer's business activities involve risks, such as accidents, equipment defects, malfunctions and failures and natural disasters. These risks expose the Issuer to potential liability for pollution and other environmental damages, personal injury, loss of life, business interruption and property damage or destruction. Potential health and safety risks arise to Issuer's employees when handling waste. Issuer has implemented internal controls and procedures to avoid potential pollution or damage to environment incidents, also procedures regarding employees' health and safety as well as having various insurance policies in place to manage the financial effects of such risks. Nevertheless, The Issuer's insurance policies could be inadequate to fully compensate for losses associated with damage to its property, assets and liability for third-party claims. In certain situations, the Issuer is not able to increase insurance coverage significantly due to economically unreasonable insurance premiums or may not be able to insure certain risks at all. Any losses exceeding amounts covered by insurance contracts may have an adverse effect on the Issuer's business operations, financial position, and cash flows.

**Risk factors related to the Bonds**

***Credit and Issuer's Default Risk***

Credit risk should be evaluated as a possibility that the Issuer might become insolvent, go bankrupt, its business being suspended or terminated, and as a result, it would be impossible to redeem the Bonds and/or pay the accrued interest to the Bondholders. Moreover, should the Issuer become insolvent, legal protection proceedings or out-of-court legal protection proceedings of the Issuer are initiated during the term of the Bonds, an investor may forfeit interest payable on, and the principal amount of, the Bonds in whole or in part. An investor is always solely responsible for the economic consequences of its investment decisions.

The Bonds constitute direct, unconditional and unsubordinated obligations of the Issuer, ranking *pari passu* without any preference among each other and with all other present and future unsecured, and unsubordinated obligations of the Issuer, which all times rank *pari passu* among themselves and at least *pari passu* with all other present and future unsecured obligations of the Issuer, save for such obligations as may be preferred by provisions of law that are both mandatory and of general application. Moreover, the Company is not restricted to provide collateral to other creditors, as a result, those creditors would be senior to the Bondholders and would have a priority right to cover claims from the collateral.

In addition, the Bonds are not bank deposits in the Issuer and are not insured by the public entity "Deposit and Investment Insurance" (in Lithuanian: *Viešoji įstaiga "Indėlių ir investicijų draudimas"*). Thus, in case of insolvency of the Issuer, the Bondholders would not receive any payments, related to Bonds from this public entity.

# RISK FACTORS IV

***Interest rate and inflation risk***

If interest rates in general or particularly with regard to obligations of corporate debtors or corporate debtors with activities in the industries sector for durations equal to the remaining term of the Bonds increase, the market value of the Bonds may decrease. The longer the remaining term of a debt instrument, the stronger is its market value affected by changes of the interest rate level. There are further factors which may affect the market value of the Bonds, including, but not limited to global or national economic factors and crises in the global or national financial or corporate sector. Bondholders should be aware that movements of the market interest rate can adversely affect the market price of the Bonds and can lead to losses for the Bondholders if they sell their Bonds.

The inflation risk is the risk of future money depreciation. The real yield from an investment is reduced by inflation. The higher the rate of inflation, the lower the real yield on the Bonds. If the inflation rate is equal to or higher than the nominal yield, the real yield is zero or even negative.

***An active secondary market for the Bonds may not develop***

The Bonds constitute a new issue of securities by the Issuer. Prior to Admission to trading on First North, which is an alternative market in Lithuania, there is no public market for the Bonds and other securities of the Issuer. Although application(s) will be made for the Bonds to be admitted to trading on First North, there is no assurance that such application(s) will be accepted, and the Bonds will be admitted to trading. In addition, Admission to trading the Bonds on an alternative market will not guarantee that a liquid public market for the Bonds will develop or, if such market develops, that it will be maintained, and neither the Issuer, nor the Arranger is under any obligation to maintain such market. If an active market for the Bonds does not develop or is not maintained, it may result in a material decline in the market price of the Bonds, and the liquidity of the Bonds may be adversely affected.

In addition, the liquidity and the market price of the Bonds can be expected to vary with changes in market and economic conditions, the financial condition and the prospects of the Issuer, as well as many other factors that generally influence the market price for securities. For example, even if the likelihood that the Issuer will be in a position to fully perform all obligations under the Bonds when they fall due actually has not decreased, market participants could be of different opinion especially if the market participant is in the opinion that the creditworthiness of corporate debtors in general or debtors operating in the industries sector adversely changed. Accordingly, due to such factors the Bonds may be trade at a discount to the price at which the Bondholders purchased/subscribed the Bonds and the market value of the Bonds may therefore decrease. Therefore, investors may be not able to sell their Bonds at all or at a price that will provide them with a yield comparable to similar financial instruments that are traded on a developed and functioning secondary market. Further, if additional and competing financial instruments are introduced on the markets, this may also result in a material decline in the market price and value of the Bonds.

# RISK FACTORS V

***Early redemption risk***

According to the General Terms and Conditions of the Bonds, the Bonds may be redeemed prematurely on the initiative of the Issuer 6 months after the Issue Date. The Issuer may choose to redeem the Bonds, subject to certain regulatory conditions and approvals, at times when prevailing interest rates may be relatively low. In such circumstances a Bondholder may not be able to reinvest the redemption proceeds in a comparable security at an effective interest rate as high as that of the relevant Bonds and may only be able to do so at a significantly lower rate. Therefore, if this early redemption right is exercised by the Issuer, the rate of return from an investment into the Bonds may be lower than initially anticipated. In addition, this optional redemption feature is likely to limit the market value of the Bonds. During any period when the Issuer may, or is perceived to be able to, elect to redeem the Bonds, the market value of the Bonds generally will not rise substantially above the price at which they can be redeemed. This also may be true prior to any redemption period.

***Amendments to the Bonds bind all Bondholders***

The Law on Protection of Interests of Bondholders requires and the terms of the Bonds contain provisions for calling Bondholders' Meetings to consider matters affecting their interests generally. These provisions permit defined majorities to bind all Bondholders including Bondholders who did not attend and vote at the relevant Bondholders' Meetings and Bondholders who voted in a manner contrary to the majority. This may incur financial losses, among other things, to all Bondholders, including such Bondholders who did not attend and vote at the relevant Bondholders' Meetings and Bondholders who voted in a manner contrary to the majority.

***Taxation of Bonds***

Potential purchasers/subscribers and sellers of the Bonds should be aware that they may be required to pay taxes or other documentary charges or duties in accordance with the laws and practices of the country where the Bonds are transferred or other jurisdictions. In some jurisdictions, no official statements of the tax authorities or court decisions may be available for financial instruments such as the Bonds. Potential investors are advised to ask for their tax advisers' advice on their individual taxation with respect to the acquisition, sale and redemption of the Bonds. Only these advisors are in a position to duly consider the specific situation of the potential investor.

# RISK FACTORS VI

***Refinancing risk***

The Issuer may be required to refinance certain or all of its outstanding debt, including the Bonds. The Issuer's ability to successfully refinance its debt is dependent on the conditions of the debt capital markets and its financial condition at such time. Even if the debt capital markets improve, the Issuer's access to financing sources at a particular time may not be available on favourable terms, or at all. The Issuer´s inability to refinance its debt obligations on favourable terms, or at all, could have a negative impact on the Issuer's operations, financial condition, earnings and on the Bondholders' recovery under the Bonds.

***Surety Risk***

The Bonds will be secured by a surety issued by UAB "Soli Tek cells". Apart from the surety referred to above, there are no other collateral or guarantees of the Issue issued by third parties. The surety securing the Issue does not guarantee that, in the event of a default of the Issuer, UAB "Soli Tek cells" will be capable to satisfy in full all the claims of the Bondholders. Therefore, in the event of the insolvency of the Issuer, its assets will be used primarily to satisfy the claims of those creditors whose claims are secured by the property and (or) mortgages of the Issuer. Therefore, there is a risk that in such an event, the assets of the Company may not be sufficient to pay the Bondholders.

Bod Lenses

# CONTACTS

**UAB BOD Lenses**
Mokslininkų g. 6A, Vilnius, Lithuania
bodlenses.com ·
+370 5 232 23 38
info@bodlenses.com

Artea

**+370 5210 3354**
**broker@artea.lt**

One
life - see
it well.